Antibody Information

General Information of This Antibody
Antibody ID
ANI0UNYBG
Antibody Name
Chimeric ICAM1 antibody (clone #R6.5)
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Intercellular adhesion molecule 1 (ICAM1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IC1-MMAE [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 62.76% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (1 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.70% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-231 CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.50% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.50% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
13.10 pM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.22 nM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast carcinoma MDA-MB-157 cells CVCL_0618
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.25 nM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
IC1-MMAF [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 84.30% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-231 CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.00% (Day 25) Positive ICAM1 expression (ICAM1 +++/++)
Method Description
IC1-MMAE (5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of MDA-MB-436 or MDA-MB-231 cells with ICAM1 expression with high expression.
In Vivo Model MDA-MB-436 CDX model
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.30 pM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Metastasis of ductal carcinoma MDA-MB-436 cells CVCL_0623
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
68.70 pM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.12 nM
Positive ICAM1 expression (ICAM1 +++/++)
Method Description
In vitro cytotoxicity of four ICAM1 ADCs against a panel of four human TNBC cell lines.
In Vitro Model Breast carcinoma MDA-MB-157 cells CVCL_0618
References
Ref 1 A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023 May 5;9(18):eabq7866. doi: 10.1126/sciadv.abq7866. Epub 2023 May 5.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.